Literature DB >> 15692969

Anti-CD20 therapy in systemic lupus erythematosus: a step closer to the clinic.

Gregg J Silverman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15692969     DOI： 10.1002/art.20857

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  4 in total

Review 1.  A perspective on B-cell-targeting therapy for SLE.

Authors:  R John Looney; Jennifer Anolik; Inaki Sanz
Journal:  Mod Rheumatol       Date:  2009-08-08       Impact factor: 3.023

2.  Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus.

Authors:  Thomas Dörner; Joerg Kaufmann; William A Wegener; Nick Teoh; David M Goldenberg; Gerd R Burmester
Journal:  Arthritis Res Ther       Date:  2006-04-21       Impact factor: 5.156

3.  Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study.

Authors:  Mónica Vigna-Perez; Berenice Hernández-Castro; Octavio Paredes-Saharopulos; Diana Portales-Pérez; Lourdes Baranda; Carlos Abud-Mendoza; Roberto González-Amaro
Journal:  Arthritis Res Ther       Date:  2006-05-05       Impact factor: 5.156

4.  New Treatments for Systemic Lupus Erythematosus on the Horizon: Targeting Plasmacytoid Dendritic Cells to Inhibit Cytokine Production.

Authors:  Laura M Davison; Trine N Jorgensen
Journal:  J Clin Cell Immunol       Date:  2017-12-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.